GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (FRA:CUS0) » Definitions » Institutional Ownership

Curis (FRA:CUS0) Institutional Ownership : 7.11% (As of Jun. 07, 2024)


View and export this data going back to . Start your Free Trial

What is Curis Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Curis's institutional ownership is 7.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Curis's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Curis's Float Percentage Of Total Shares Outstanding is 99.88%.


Curis Institutional Ownership Historical Data

The historical data trend for Curis's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curis Institutional Ownership Chart

Curis Historical Data

The historical data trend for Curis can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 7.75 8.01 6.25 6.37 6.54 6.76 6.83 6.80 7.11 7.11

Curis Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Curis (FRA:CUS0) Business Description

Industry
Traded in Other Exchanges
Address
128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis (FRA:CUS0) Headlines

No Headlines